Stratec

Valuation Analysis

About the Company

Stratec en bref

Stratec (SBS.DE) is currently trading at 18,22 € with a market capitalization of 193 M €. The 52-week range spans from 16,30 € to 33,10 €; the current price is 45% below the yearly high. Year-over-year revenue growth stands at -11.5%.

💰 Dividende

Stratec currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent Stratec (SBS.DE) au consensus : Acheter. L'objectif de cours moyen est de 25,40 €, soit un potentiel de +39.41% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,00 € à 37,00 €.

Stratec : la thèse d'investissement en détail

Stratec (SBS.DE) operates in the Healthcare — specifically Medical Devices — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 39.41% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -11.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

With a PEG ratio of 0.98, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 39.41% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Stratec?

Compare top-rated brokers — low fees, trusted providers, fully regulated.